Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T18:48:28.307Z.
Calculation as of: 2026-10-06T18:48:28.307Z.
Quote observation: 2026-10-06T18:27:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 967c3c4e1026402272b5761d24a9cd8122a999a0fe4ad26a1d84866f163ab752
PEG RATIO
N/A
Xilio Therapeutics, Inc.
Market Cap
$60.03M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Xilio Therapeutics, Inc. (XLO) | $60.03M | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $59.76M | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.94M | N/A |
| Adicet Bio, Inc. (ACET)vs › | $59.41M | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $61.87M | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $58.59M | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.55M | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $58.32M | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $58.16M | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $62.50M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
